Quantcast

Latest Retinitis pigmentosa Stories

2008-10-30 09:00:41

StemCells, Inc. (NASDAQ:STEM) reported today that its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells), when transplanted into a well-established animal model, can protect the retina from progressive degeneration. Retinal degeneration leads to loss of vision in diseases such as age-related macular degeneration and retinitis pigmentosa. This promising study was conducted by Dr. Raymond Lund, a researcher and professor at the Casey Eye Institute at Oregon Health...

2008-10-21 09:00:54

CUMBERLAND, R.I., Oct. 21 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today the opening of its new 27,000 square-foot GMP manufacturing facility in Cumberland, Rhode Island. With support from the Rhode Island Economic Development Corporation (RIEDC) and its financing programs, Rhode Island Industrial Facilities Corporation (RIIFC) and Rhode Island...

2008-10-09 09:00:52

VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ -- QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today that it has initiated a Phase I safety study in healthy adults of QLT091001, an orally administered synthetic retinoid replacement therapy for 11-cis-retinal, which is a key biochemical component of the visual retinoid cycle. The drug is being developed for the potential treatment of Leber's Congenital Amourosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal...

2008-09-04 12:00:33

Neurotech Pharmaceuticals, a biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, has announced that the FDA has granted fast track designations for NT-501 for the treatment of visual loss in two indications - retinitis pigmentosa and the dry form of age-related macular degeneration. Neurotech is conducting two Phase II/III trials of NT-501 for the treatment of visual loss associated with retinitis pigmentosa (RP)-one consisting of...

2008-09-03 09:00:46

LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designations for NT-501 for the treatment of visual loss in two indications -- retinitis pigmentosa (RP) and the dry form of age-related macular degeneration (dry AMD). NT-501 is an intraocular, cell containing...

2008-08-14 15:00:59

Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system (CNS) and autoimmune diseases, today announced its clinical update and results for its second quarter of 2008. A conference call has been scheduled for 4:30 p.m. EDT today. In order to participate in the conference call, please call toll free: 888-256-9124 and international dial-in: 913-312-0830. A replay of the conference...

2008-06-30 15:03:02

Case Western Reserve University School of Medicine, in collaboration with Copernicus Therapeutics, Inc. and Polgenix, Inc., was selected to receive $3.9 million in funding from the Ohio Biomedical Research Commercialization Program (BRCP) as awarded by Lieutenant Governor Lee Fisher, Chair of the Ohio Third Frontier Commission. The BRCP awards grants that support Ohio-based biomedical and biotechnology research leading to commercialization and long-term improvements to the health of...

0673e82cfc6fdf0b5674da1904dd87691
2008-04-21 12:10:00

Two blind patients in Britain became the first new owners of an artificial electronic retinal device last week.Surgeons at Moorfields Eye Hospital in London successfully transplanted the bionic eye, which uses a video camera and transmitter mounted on a pair of glasses.The artificial retina enables patients to discriminate rudimentary images of motion, light and dark.The operations were carried out by Mr Lyndon da Cruz, a consultant retinal surgeon, and his team from the Vitreo Retinal...

2008-04-03 18:00:42

IRVINE, Calif., April 3, 2008 (PRIME NEWSWIRE) -- Vitreoretinal Technologies, Inc. (VRT) today announced the enrollment of the first patients in a multinational Phase III clinical trial for evaluation of the safety and efficacy of VRT's investigational drug Vitreosolve(r) for diabetic retinopathy patients. The first patients were enrolled and treated at clinical sites both in the U.S. and India. Vitreoretinal Technologies (VRT) is a specialty pharmaceutical company with a specific focus on...

591b3cb758fbd87c4713b32c4e431f0d1
2008-03-18 15:55:00

New hope for regenerating the human retina damaged by disease or injuryScientists at Schepens Eye Research Institute have discovered what chemical in the eye triggers the dormant capacity of certain non-neuronal cells to transform into progenitor cells, a stem-like cell that can generate new retinal cells. The discovery, published in the March issue of Investigative Ophthalmology and Visual Science (IOVS), offers new hope to victims of diseases that harm the retina, such as macular...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.